Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Marc G. Ghany – 1 August 2017 – The majority of persons currently treated for chronic hepatitis B require long‐term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials.

Claudia Filozof, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Sanyal – 1 August 2017 – Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the fact that most patients are undiagnosed, and the requirement for sequential liver biopsies create substantial challenges for clinical development.

Xiao‐Dong Zhou, Qin‐Fen Chen, Dan‐Qin Sun, Chen‐Fei Zheng, Dong‐Jie Liang, Jian Zhou, Song‐Jie Wang, Wen‐Yue Liu, Sven Poucke, Xiao‐Dong Wang, Ke‐Qing Shi, Wei‐Jian Huang, Ming‐Hua Zheng – 1 August 2017 – Serum creatinine measurement demonstrates a poor specificity and sensitivity for the early diagnosis of acute kidney injury (AKI) in patients with cirrhosis. The existing model for end‐stage liver disease (MELD) score reveals multiple pitfalls in critically ill patients with cirrhosis and acute kidney injury (CAKI).

Claudia Filozof, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Sanyal – 1 August 2017 – Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the fact that most patients are undiagnosed, and the requirement for sequential liver biopsies create substantial challenges for clinical development.

31 July 2017

Jinyang Gu, Seogsong Jeong, Qiang Xia – 31 July 2017

Fahrettin Haczeyni, Hans Wang, Vanessa Barn, Auvro R. Mridha, Matthew M. Yeh, W. Geoffrey Haigh, George N. Ioannou, Yun‐Jung Choi, Charles A. McWherter, Narcissus C.‐H. Teoh, Geoffrey C. Farrell – 31 July 2017 – Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia.

Gonzalo Sapisochin, Jordi Bruix – 31 July 2017

31 July 2017

Fumika Shigiyama, Naoki Kumashiro, Yasuhiko Furukawa, Takashi Funayama, Kageumi Takeno, Noritaka Wakui, Takashi Ikehara, Hidenari Nagai, Hikari Taka, Tsutomu Fujimura, Hiroshi Uchino, Yoshifumi Tamura, Hirotaka Watada, Tetsuo Nemoto, Nobuyuki Shiraga, Yasukiyo Sumino, Takahisa Hirose – 29 July 2017 – Nonalcoholic fatty liver disease (NAFLD) plays a crucial role in type 2 diabetes and hepatocellular carcinoma. The major underlying pathogenesis is hepatic insulin resistance.